The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer.
 
Aparna Raj Parikh
Consulting or Advisory Role - Driver, Inc; Driver, Inc; Driver, Inc; Driver, Inc; Eisai; Eisai; Eisai; Eisai; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; PureTech; PureTech; PureTech; PureTech
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Eisai; Eisai; Eisai; Eisai
 
Madeleine Fish
No Relationships to Disclose
 
Emily E. Van Seventer
No Relationships to Disclose
 
Kathryn Fosbenner
No Relationships to Disclose
 
Katie Kanter
No Relationships to Disclose
 
Jill N. Allen
No Relationships to Disclose
 
Jeffrey William Clark
Consulting or Advisory Role - Emas pharma; Emas pharma; Emas pharma; Emas pharma
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
 
Bruce Giantonio
No Relationships to Disclose
 
Colin D. Weekes
Honoraria - Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly; Merrimack; Merrimack; Merrimack; Merrimack
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Merrimack; Merrimack; Merrimack; Merrimack
Research Funding - Abbvie; Abbvie; Abbvie; Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Halozyme; Halozyme; Halozyme; Halozyme; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Millennium; Millennium; Millennium; Millennium
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly
 
Samuel J. Klempner
Stock and Other Ownership Interests - TP Therapeutics; TP Therapeutics; TP Therapeutics; TP Therapeutics
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Lilly; Lilly; Lilly; Lilly
Speakers' Bureau - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst)
 
Joseph Wang Franses
Stock and Other Ownership Interests - Biogen; Biogen; Biogen; Biogen; Merck; Merck; Merck; Merck
Consulting or Advisory Role - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine
 
Eric Roeland
Consulting or Advisory Role - AIM Specialty Health; AIM Specialty Health; AIM Specialty Health; AIM Specialty Health; Asahi Kasei; Asahi Kasei; Asahi Kasei; Asahi Kasei; BASF; BASF; BASF; BASF; Helsinn Healthcare (Inst); Helsinn Healthcare (Inst); Helsinn Healthcare (Inst); Helsinn Healthcare (Inst); Immuneering; Immuneering; Immuneering; Immuneering; Napo Pharmaceuticals; Napo Pharmaceuticals; Napo Pharmaceuticals; Napo Pharmaceuticals; Oragenics; Oragenics; Oragenics; Oragenics; Pronova (Inst); Pronova (Inst); Pronova (Inst); Pronova (Inst); Vector Oncology; Vector Oncology; Vector Oncology; Vector Oncology
 
Lipika Goyal
Consulting or Advisory Role - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Jennifer Yon-Li Wo
No Relationships to Disclose
 
Theodore S. Hong
Consulting or Advisory Role - Clinical Genomics; Clinical Genomics; Clinical Genomics; Clinical Genomics; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
 
Isobel Fetter
No Relationships to Disclose
 
Giulia Siravegna
No Relationships to Disclose
 
Nora K. Horick
No Relationships to Disclose
 
Ryan Bruce Corcoran
Stock and Other Ownership Interests - Avidity Biosciences; Avidity Biosciences; Avidity Biosciences; Avidity Biosciences; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; nRichDx; nRichDx; nRichDx; nRichDx; Revolution Medicines; Revolution Medicines; Revolution Medicines; Revolution Medicines
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Avidity Nanomedicines; Avidity Nanomedicines; Avidity Nanomedicines; Avidity Nanomedicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Elicio Therapeutics; Elicio Therapeutics; Elicio Therapeutics; Elicio Therapeutics; FOGPharma; FOGPharma; FOGPharma; FOGPharma; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Genentech; Genentech; Genentech; Genentech; Loxo; Loxo; Loxo; Loxo; Merrimack; Merrimack; Merrimack; Merrimack; N-of-One; N-of-One; N-of-One; N-of-One; Novartis; Novartis; Novartis; Novartis; nRichDx; nRichDx; nRichDx; nRichDx; Revolution Medicines; Revolution Medicines; Revolution Medicines; Revolution Medicines; Roche; Roche; Roche; Roche; Roivant; Roivant; Roivant; Roivant; Shionogi; Shionogi; Shionogi; Shionogi; Shire; Shire; Shire; Shire; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Symphogen; Symphogen; Symphogen; Symphogen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Warp Drive Bio; Warp Drive Bio; Warp Drive Bio; Warp Drive Bio
Research Funding - Asana Biosciences; Asana Biosciences; Asana Biosciences; Asana Biosciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Sanofi; Sanofi; Sanofi; Sanofi
 
Ryan David Nipp
No Relationships to Disclose